Study on gene markers in lung cancer for treatment resistance
Part of Cancer, Lungs & breathing clinical trials.
This study looks at genetic markers in two types of lung cancer (small cell and large cell neuroendocrine) to understand why some tumors stop responding to a standard treatment that combines chemotherapy with immunotherapy. If you have one of these cancers and are about to start this treatment, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have been diagnosed with advanced small cell lung cancer or large cell neuroendocrine lung cancer.
- You are about to start a standard treatment that includes chemotherapy (cisplatin or carboplatin) plus an immunotherapy drug (atezolizumab or durvalumab).
- You have not had any prior chemotherapy or immunotherapy for this cancer.
- You are willing to give blood and tumor tissue samples for genetic testing.
- You can attend regular follow-up visits and provide additional samples during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects blood and tumor samples from people newly diagnosed with small cell lung cancer to study how genetic markers can predict treatment success and monitor disease over time.
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This study uses biomarker tests on your tumor to find a personalized treatment after initial chemotherapy. You will be assigned to one of four treatment groups based on your biomarker results.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.